Veana Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Veana Therapeutics, Inc. - overview
Established
2012
Location
Portland, OR, US
Primary Industry
Biotechnology
About
Established in 2012 by Emmanuel Akporiaye, and based in Oregon, US, Veana Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing oral cancer treatments. In 2024, Veana Therapeutics, Inc. raised venture funding from the Cancer Fund.
The firm’s technology, known as VIMO, utilizes compounds that target and destroy the mitochondria of cancer cells, inducing cell death and enhancing immune response. The flagship product, VT-101, is a proprietary oral formulation of alpha-TEA (alpha-tocopheryloxyacetic acid) designed to complement existing therapies such as checkpoint inhibitors. The VIMO platform aims to improve anti-tumor activity by stimulating immune system response through cancer-specific cell destruction and antigen presentation.
Current Investors
Cancer Fund
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.veana-therapeutics.com
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Veana Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.